References
- CottrellMLHadzicTKashubaADClinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravirClin Pharmacokinet2013521198199423824675
- SongIBorlandJChenSEffect of atazanavir and atazanavir/ritonavir on the pharmacokinetics of the next-generation HIV integrase inhibitor, S/GSK1349572Br J Clin Pharmacol201172110310821342217
- EronJJClotetBDurantJSafety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the Viking studyJ Infect Dis2013207574074823225901
- LanzafameMLattuadaENicolèSDolutegravir 50 mg thrice weekly plus atazanavir 400 mg daily in a long-term virologically suppressed HIV-infected patientInt J STD AIDS201728772672827789848
- PontaliETorresinAACenderelloGLow dose of unboosted atazanavir plus dolutegravir as simplification strategy for HIV-infected patients receiving antiretroviral therapy9th Italian conference on AIDS and antiviral research2017, June 12–14Siena, Italyposter 101